Evidence map›Paper›PMID 40966644›Full record

ArticleBriefings in bioinformatics2025

Graph-based deep learning for integrating single-cell and bulk transcriptomic data to identify clinical cancer subtypes.

Yixin Liu, Dandan Zhang, Tianyu Liu, Ao Wang, Guohua Wang, Yuming Zhao

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yixin LiuModern Education Technology Center, Harbin Medical University, 157 Baojian Road, Nangang District, Harbin 150080, China.ORCID 0000-0002-5988-722X
Dandan ZhangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Harbin Medical University, 199 Dazhi Street, Nangang District, Harbin 150007, China.
Tianyu LiuCollege of Computer and Control Engineering, Northeast Forestry University, 26 Hexing Road, Xiangfang District, Harbin 150040, China.
Ao WangCollege of Computer and Control Engineering, Northeast Forestry University, 26 Hexing Road, Xiangfang District, Harbin 150040, China.
Guohua WangCollege of Computer and Control Engineering, Northeast Forestry University, 26 Hexing Road, Xiangfang District, Harbin 150040, China.ORCID 0000-0001-7381-2374
Yuming ZhaoCollege of Computer and Control Engineering, Northeast Forestry University, 26 Hexing Road, Xiangfang District, Harbin 150040, China.ORCID 0000-0001-7219-0999

Funding

National Natural Science Foundation of China 62472129National Natural Science Foundation of China 62473119
6 · The paper itself

Abstract

The integration of single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data has become essential for deciphering the complex heterogeneity of cancer and identifying clinical cancer subtypes. However, the inherent challenges posed by the high dimensionality, sparsity, and noise characteristics of scRNA-seq data have significantly hindered its widespread clinical translation. To address these limitations, we introduce single-cell and bulk transcriptomic graph deep learning, a graph-based deep learning method that synergistically integrates scRNA-seq and bulk transcriptomic data to precisely identify cancer subtypes and predict clinical outcomes. scBGDL constructs sample-specific gene graphs modeling complex gene-gene interactions and cellular relationships. The architecture employs Graph Attention Networks for feature aggregation, MinCutPool layers for dimensionality reduction, and Transformer modules to capture high-order biological dependencies. Independently validated in each of 16 distinct The Cancer Genome Atlas cancer types, scBGDL significantly outperformed existing methods in prognostic accuracy (mean C-index: 0.7060 versus 0.6709 max competitor), demonstrating robustness and generalizability to diverse transcriptional architectures. To demonstrate clinical versatility, we further evaluated scBGDL in three therapeutic contexts using multicenter cohorts: lung adenocarcinoma survival prediction (n = 1099), epithelial ovarian cancer platinum-based chemotherapy response (n = 762), skin cutaneous melanoma immunotherapy outcome (n = 305). scBGDL consistently delivered robust risk stratification (log-rank P < 0.05 across cohorts), identified key driver edges, and uncovered clinically relevant biological interpretations. By enabling multimodal data integration and interpretable biological insights, scBGDL advances precision oncology for prognosis prediction, therapy optimization, and biomarker discovery. The source code for scBGDL model is available online (https://github.com/NEFLab/scBGDL).

Indexed as

Deep LearningNeoplasmsSingle-Cell AnalysisTranscriptomeGene Expression ProfilingHumansPrognosiscancer subtypesdata integrationgraph-based deep learningprediction modelsingle-cell RNA sequencing

Identifiers

PMID40966644
PMCPMC12423395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.